,dinutuximab,sargramostim,trastuzumab deruxtecan
roche,daiichi sankyo,partner therapeutics,astrazeneca,united therapeutics corp
['dinutuximab', 'sargramostim', '1000']
abstract 10003 #asco22 - pilot induction regimen incorporating dinutuximab (din) + sargramostim for treatment of newly diagnosed hr #neuroblastoma ( anbl17p1) din in induction does not impede ability to deliver tx later. now onto phase 3 study #childhoodcancer #pedcsm 
#Cancer #Pharmacist (#OncoPharm) | #ChildhoodCancer #Advocate | Michigan ‘96 - #GoBlue | Tweets are not medical advice | Interests ???????????????????????